MACH32 has been awarded an EZ-BAA Advanced Research and Development contract from Biomedical Advanced Research and Development Authority (BARDA) valued at approximately $750,000 USD. The contract supports MACH32’s development of an intramuscular formulation of tranexamic acid (TXA) designed to treat life-threatening bleeding after traumatic injury, aiming to make TXA available to all first responders in an autoinjector format.
Company Information
Company
MACH32
Location
Alberta, Canada
About
MACH32 is a medical technology company based in Alberta, Canada, with the primary goal of stopping people from bleeding to death.